ALT 241011 10.00C (ALT241011C10000) Stock Options, News & Quotes

0.15
0.000.00%

15min DelayClose Sep 23 13:25 ET

0.00High0.00Low

SymbolStock Name

Latest PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Clembot82

Sep 30 12:54

Wish I had some dry powder

$Altimmune (ALT.US)$ Money tied up on some other plays, well see how long is at these levels. There are always more opportunities to come. 🐂 📈

frogoracletrading

Sep 21 12:45

$ALT Support / Resistance Levels

Watching for consolidation over the 7.40 top of the POC to setup a push to 10.00+
Larger Image: tradingview.com...
$Altimmune (ALT.US)$

Trytosaveabit

Sep 10 06:56

Update

$Altimmune (ALT.US)$ Altimmune Presents Data From Its Phase 2, MRI-Based Body Composition Sub-study Of Pemvidutide In Subjects With Overweight And Obesity
Benzinga· 1 min ago
In an MRI sub-study of 67 subjects from the Phase 2 MOMENTUM obesity trial, 50 of whom were treated with pemvidutide for 48 weeks, the lean loss ratio, defined as the change in lean mass compared to the change in total mass, was 21.9%.
Lean mass preservation was greater in subjects aged 60 years and older, in whom the ...

Jaguar8

Sep 10 06:46

NEWS

$Altimmune (ALT.US)$
Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes
Altimmune presented results from a Phase 2 MRI-based body composition sub-study of pemvidutide at the 60th Annual Meeting of the European Association for the Study of Diabetes. The study, involving 67 subjects from the MOMENTUM obesity trial, showed promising outcomes for pemvidutide, a novel GLP-1/glucagon dual receptor...

frogoracletrading

Aug 19 16:08

$ALT Support / Resistance Levels

Another strong day for ALT. 7.65 is resistance now. Support is at 7.40 the top of the POC.
Larger Image: tradingview.com...
$Altimmune (ALT.US)$